{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.88","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.75","statisticalMethod":"Likelihood Based Score Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"7.1","value":"6.3"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"6.1","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"332"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the first documented progressive disease (PD) per meso-modified-Response Evaluation Criteria in Solid Tumors (Meso-modified RECIST) based on independent radiology review or death due to any cause, whichever occurred first. Meso-modified RECIST was created and validated for disease measurement in pleural mesothelioma. Per meso-modified RECIST, PD was defined as ≥20% increase in the total tumor measurement over the nadir measurement or the appearance of ≥1 new lesions. The final analysis for PFS per Meso-modified RECIST by independent radiology review was planned and performed at the time of the protocol pre-specified final statistical analysis with a data cut-off of 15-July-2011. PFS analysis per Meso-modified RECIST by independent radiology review is reported here for all randomized participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"OG000","title":"Vorinostat"},{"description":"Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All participants randomized to a study arm.","reportingStatus":"POSTED","timeFrame":"Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}